Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1967 2
1972 1
1979 1
1980 2
1981 3
1982 3
1983 4
1984 1
1990 2
1991 1
1994 1
1997 2
1998 1
1999 1
2000 3
2001 3
2003 4
2005 3
2006 2
2007 3
2008 3
2009 3
2010 1
2011 2
2012 3
2013 3
2015 4
2016 6
2017 2
2018 1
2019 1
2020 1
2021 2
2022 5
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Stafiba: A STAT5-Selective Small-Molecule Inhibitor.
Eckhardt KS, Münzel T, Gräb J, Berg T. Eckhardt KS, et al. Chembiochem. 2023 Jan 3;24(1):e202200553. doi: 10.1002/cbic.202200553. Epub 2022 Nov 24. Chembiochem. 2023. PMID: 36300584 Free PMC article.
Phosphorus L(2,3)-edge XANES: overview of reference compounds.
Kruse J, Leinweber P, Eckhardt KU, Godlinski F, Hu Y, Zuin L. Kruse J, et al. Among authors: eckhardt ku. J Synchrotron Radiat. 2009 Mar;16(Pt 2):247-59. doi: 10.1107/S0909049509000211. Epub 2009 Jan 16. J Synchrotron Radiat. 2009. PMID: 19240337 Review.
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova VS, Menter T, Dirnhofer S, Scheibe B, Gadient S, Eckhardt K, Zucca E, Driessen C, Renner C. Novak U, et al. Among authors: eckhardt k. EClinicalMedicine. 2023 Sep 22;64:102221. doi: 10.1016/j.eclinm.2023.102221. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37781158 Free PMC article.
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle DL, Hess D, Moccia AA, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W. Stathis A, et al. Among authors: eckhardt k. Blood Adv. 2022 Jul 12;6(13):3911-3920. doi: 10.1182/bloodadvances.2021006520. Blood Adv. 2022. PMID: 35537101 Free PMC article. Clinical Trial.
Early Ultrastructural Changes in Biopsies From Patients With Symptomatic CKD of Uncertain Etiology.
Daniel C, Enghard P, Ratnatunga N, Wijetunge S, Wazil AWM, Zwiener C, Barth JAC, Chandrajith R, Klewer M, Eckhardt KU, Amann K, Freund P, Premarathne S, Pushpakumara WDRN, Nanayakkara N. Daniel C, et al. Among authors: eckhardt ku. Kidney Int Rep. 2022 Dec 31;8(3):642-657. doi: 10.1016/j.ekir.2022.12.022. eCollection 2023 Mar. Kidney Int Rep. 2022. PMID: 36938087 Free PMC article.
Mutagenicity studies with the mouse spot test.
Gocke E, Wild D, Eckhardt K, King MT. Gocke E, et al. Among authors: eckhardt k. Mutat Res. 1983 Apr;117(1-2):201-12. doi: 10.1016/0165-1218(83)90168-4. Mutat Res. 1983. PMID: 6835259
84 results